Analysts Anticipate Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Will Post Quarterly Sales of $60.98 Million

Equities analysts forecast that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will announce sales of $60.98 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Alnylam Pharmaceuticals’ earnings. The highest sales estimate is $72.50 million and the lowest is $54.00 million. Alnylam Pharmaceuticals reported sales of $2.07 million during the same quarter last year, which suggests a positive year over year growth rate of 2,845.9%. The company is expected to announce its next earnings results on Wednesday, November 6th.

According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full year sales of $206.25 million for the current fiscal year, with estimates ranging from $174.30 million to $236.00 million. For the next fiscal year, analysts forecast that the business will report sales of $430.15 million, with estimates ranging from $388.26 million to $490.70 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.02) EPS for the quarter, topping the consensus estimate of ($2.06) by $0.04. Alnylam Pharmaceuticals had a negative return on equity of 56.42% and a negative net margin of 848.70%. The firm had revenue of $38.20 million for the quarter, compared to the consensus estimate of $42.24 million. During the same quarter last year, the company earned ($1.61) earnings per share. The business’s revenue for the quarter was up 27.8% compared to the same quarter last year.

ALNY has been the topic of several recent analyst reports. BidaskClub raised Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, June 11th. ValuEngine raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Morgan Stanley decreased their target price on Alnylam Pharmaceuticals from $126.00 to $124.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. BMO Capital Markets lifted their target price on Alnylam Pharmaceuticals from $126.00 to $128.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Finally, Barclays reissued a “buy” rating and set a $125.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, August 7th. Six analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Alnylam Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $121.13.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue boosted its holdings in shares of Alnylam Pharmaceuticals by 1.4% in the 2nd quarter. State of Alaska Department of Revenue now owns 11,061 shares of the biopharmaceutical company’s stock worth $802,000 after purchasing an additional 152 shares during the period. World Asset Management Inc increased its position in Alnylam Pharmaceuticals by 6.0% during the 2nd quarter. World Asset Management Inc now owns 3,190 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 180 shares in the last quarter. Metropolitan Life Insurance Co NY increased its position in Alnylam Pharmaceuticals by 3.5% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 6,557 shares of the biopharmaceutical company’s stock valued at $612,000 after buying an additional 221 shares in the last quarter. US Bancorp DE increased its position in Alnylam Pharmaceuticals by 70.2% during the 2nd quarter. US Bancorp DE now owns 628 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 259 shares in the last quarter. Finally, Meeder Asset Management Inc. increased its position in Alnylam Pharmaceuticals by 332.9% during the 1st quarter. Meeder Asset Management Inc. now owns 342 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 263 shares in the last quarter. Institutional investors and hedge funds own 87.30% of the company’s stock.

Shares of NASDAQ ALNY traded down $1.21 during trading on Thursday, hitting $82.16. The company had a trading volume of 633,761 shares, compared to its average volume of 852,426. The stock has a 50 day simple moving average of $76.36 and a 200 day simple moving average of $78.83. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.16 and a current ratio of 6.28. Alnylam Pharmaceuticals has a 12 month low of $60.27 and a 12 month high of $124.21. The firm has a market capitalization of $9.23 billion, a P/E ratio of -10.85 and a beta of 2.46.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Read More: Day Trading – Risk Worth the Reward?

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.